Technology | 2009.10.21
Argos Therapeutics Presents Positive Phase 2 Viral Load and Immune Response Data for Arcelis™ HIV Program at the AIDS Vaccine 2009 Conference
DURHAM, N.C. and PARIS--(BUSINESS WIRE)--Argos Therapeutics today announced two presentations at the AIDS Vaccine 2009 conference, detailing positive viral load, immune response and safety data from an ongoing Phase 2a trial of AGS-004, its personalized immunotherapy candidate. AGS-004 is a product of the Company’s Arcelis™ technology, and is a personalized, RNA-loaded, dendritic cell-based immunotherapy that is perfectly matched to each patient’s unique HIV viral burden. The p
For more information, please visit
http://www.businesswire.com/news/home/20091021005177/en
